Northwest Biotherapeutics Inc (OTC: NWBO), which has been working on the development of DCVax customized immune therapies meant to guard against tumor cancers, saw its stock make considerable gains in 2020.
During the course of 2020, the stock had gone on a remarkable run from its 52-week low of $0.15 a share and ended up making gains of as cosmic as 950%. However, things have slowed down somewhat in 2021 and the Northwest stock has largely been trading within a range so far.
The last significant news with regards to Northwest was back in March. Back on March 16, the company announced that it had completed the development with regards to the initial production capacity of its advanced manufacturing facility located in Sawston, United Kingdom. At the time, the company had announced that it was in the concluding stages of its preparation with regards to submitting an application to the UK Medicines and Health Products Regulatory Authority.
Finance and Entertainment Reporter
Richard is a bottle of wine – the older the sweeter. He has already found the sweetest hobby in writing entertainment and finance news for Own Snap. Readers get the updated posts regularly from him searching for real-time news.